Jianxin R&D creates a multi-dimensional business map for Health Yuan, which is selected as one of the top 500 innovative enterprises.
Published Time:
2022-08-15
A high-quality entrepreneurial and innovative environment is attractive to cities and fosters creativity for businesses. On August 8, Zhejiang University School of Management and Shenzhen Press Group's Deep New Communication Think Tank jointly released the "2022 China Listed Companies Innovation Index Report." The report shows that Shenzhen, known as the "City of Innovation," has 34 companies on the top 500 list of the Innovation Index, including Healthy Yuan ( 11.10 -1.60% , Check Stock )、 Mindray Medical ( 299.29 -2.24% , Check Stock )、 Goer ( 9.16 -1.08% , Check Stock etc., ranking third among all cities, second only to Shanghai and Beijing.
According to the introduction, the report selected 2842 China A-shares listed companies as the evaluation objects. It constructed an evaluation model based on two dimensions: innovation potential and innovation efficiency. The evaluation method for the innovation index was built based on seven indicators: R&D investment scale, R&D personnel scale, patent scale data, average sales profit margin, R&D intensity index, technological efficiency, and business model novelty. Three rankings were produced: "2021 China Listed Companies Innovation Index Top 500," "2021 China Listed Companies Innovation Potential Top 200," and "2021 China Listed Companies Innovation Efficiency Top 200."
According to the industry distribution summarized in the report, the top industries in various provinces mainly include chemical raw materials and chemical product manufacturing, electrical machinery and equipment manufacturing, computer communication and other electronic equipment manufacturing, and special equipment manufacturing. For the capital market innovation capability is one of the leading indicators of the investment value of listed companies. The report selects listed companies with high rankings in the innovation index to form an investment portfolio, and calculates their portfolio rate of return using market capitalization as the weight.
The gene of innovation and change has always flowed in the blood of Shenzhen enterprises. Located in this city, Joincare Pharmaceutical Group Industry Co., Ltd. mainly focuses on the great health industry. Based on its own strong continuous technological innovation, it is constantly innovating while also promoting the rapid development of the Greater Bay Area pharmaceutical industry. After decades of cultivation and accumulation, Healthy Yuan has developed into a comprehensive innovative R&D pharmaceutical group covering multiple fields, including chemical preparations, traditional Chinese medicine preparations, chemical raw materials and intermediates, diagnostic reagents and equipment, and health products. It possesses a highly efficient and high-quality R&D platform, a complete industrial chain, and a rich product pipeline layout.
For many years, Healthy Yuan has always adhered to R&D innovation as its driving force, focusing on patient interests. It actively introduces senior domestic and foreign experts and innovative talents, increases R&D investment, and utilizes overseas strategic alliances, etc., focusing on the construction of innovative high-barrier complex preparation technology platforms such as inhalation administration, antibody technology, sustained-release microspheres, and lipid microemulsions, continuously improving its R&D competitiveness. In 2021, Healthy Yuan's total R&D expenses amounted to 1.397 billion yuan, a year-on-year increase of 30.36%. According to statistics from the Pharmaceutical Intelligence Listed Company Product R&D Details Database, Healthy Yuan and its subsidiary Lizhu Group ( 31.97 -0.59% , Check Stock ) ranked seventh and ninth in the domestic pharmaceutical industry in 2021 in terms of R&D investment, respectively, with a high change ranking among the top four, maintaining a high level in the same industry.
According to previous reports, Professor Guo Bin, head of the compilation team of the "2022 China Listed Companies Innovation Index Report" and professor at Zhejiang University School of Management, stated that digital transformation and domestic substitution in the future hold significant opportunities, and hopes that innovative enterprises in Shenzhen can make greater improvements in business models and hard technology. This report has been released for three consecutive years, and has received widespread attention and high recognition from society in the previous two years, with its influence radiating across the country.
Source: Financial World